Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 12.5mg;  ; valsartan 160mg;  ;  ;   - film coated tablet - 12.5mg/160mg - active: hydrochlorothiazide 12.5mg   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone ethanol hypromellose iron oxide red macrogol 8000 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - hydrochlorothiazide 25mg;  ; valsartan 160mg;  ;  ;   - film coated tablet - 25mg/160mg - active: hydrochlorothiazide 25mg   valsartan 160mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide black iron oxide red iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. these fixed dose combinations should be used as second line.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - acetazolamide 250mg;   - tablet - 250 mg - active: acetazolamide 250mg   excipient: calcium hydrogen phosphate dihydrate magnesium stearate povidone sodium starch glycolate starch - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - acetazolamide sodium 549.5mg equivalent to 500 mg acetazolamide;   - powder for injection - 500 mg - active: acetazolamide sodium 549.5mg equivalent to 500 mg acetazolamide   excipient: hydrochloric acid nitrogen sodium hydroxide - for adjunctive treatment of oedema due to congestive heart failure; drug-induced oedema;

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 10mg;   - tablet - 10 mg - active: baclofen 10mg   excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose povidone wheat starch

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 2 mg/ml - solution for injection - 10 mg/5ml - active: baclofen 2 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 0.5 mg/ml - solution for infusion - 0.5 mg/ml - active: baclofen 0.5 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 2 mg/ml - solution for infusion - 2 mg/ml - active: baclofen 2 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.